How your eligible patients may apply for financial assistance for their Thyrogen
The Thyrogen Co-Pay Program
To help make treatment costs and co-pays more affordable, we created the Thyrogen Co-Pay Program. Through the program, financial assistance is available to help eligible*, commercially insured patients receive Thyrogen at:
How Your Eligible Patients may Apply for the Thyrogen Co-Pay program
- If they have commercial insurance, they may be eligible through the Thyrogen Co-Pay Program
- Patients can learn more here: https://www.thyrogen.com/patients
- If your patient qualifies, he or she will receive a Thyrogen Co-Pay Card in the mail. Your patient may use the Thyrogen Co-Pay Card to pay up to $1,000 of out of pocket expenses.
* IMPORTANT NOTICE: The Copay Program does not cover prescriptions eligible to be reimbursed, in whole or in part, by a state or federal health care program, including but not limited to Medicare, Medicare Advantage Plans (Example: FreedomBlue offered through BlueCross Blue Shield), Medicare Part D, Medicaid, Medigap, Veterans Affairs, Department of Defense, or TRICARE.
In accordance with State law, the Program does not reimburse infusion-related charges for commercially insured patients residing in Massachusetts, Michigan, or Rhode Island. (Charitable Access Program patients residing in these states are eligible to receive assistance for infusion-related charges while they are receiving charitable drug.) No claim for reimbursement of any out-of-pocket expenses covered by the Co-Pay Program may be submitted to any third-party payer, whether public or private. The Co-Pay Program is available only in the United States and cannot be combined with any other rebate/coupon, free trial, or similar offer. Co-Pay benefits are not transferable. Sanofi reserves the right to rescind, revoke, modify, or amend this program without notice. Through your participation in the Co-Pay Program, you understand and agree to comply with the terms and conditions set forth above.
The Thyrogen Patient Assistance Program (PAP)
With the Thyrogen Patient Assistance Program, eligible* patients may receive Thyrogen free of charge if they:
- Medically need Thyrogen, but no longer have insurance.
- If their insurance does not cover Thyrogen.
- Download and complete the Thyrogen Patient Assistance Program Application Form.
*Patients will need to meet the eligibility criteria, including household income to qualify. The ThyrogenONE team will research each patient’s situation and determine eligibility. For more information call 1-88-THYROGEN (1-888-497-6436).
Reimbursement FAQ’s from your patients
Your patient’s insurance plan will determine if Thyrogen is covered by major medical or pharmacy benefit or both. Your patients may obtain this information from their insurance plan. Your patient may also call 1-88-THYROGEN (1-888-497-6436) to speak with a dedicated Case Manager.
Your patients may call 1-88-THYROGEN (1-888-497-6436) to determine if they are eligible for the Thyrogen Co-Pay Assistance Program. If they are, they will receive the ThyrogenCo-Pay Card in the mail, which will cover up to $1,000 of their out of pocket (OOP) expenses. Patients may call their insurance company to determine if they have additional OOP above the $1,000 co-pay assistance. If they do, their insurance company will tell them how much it is.
Thyrogen is covered by Medicare Part B when it is administered in the outpatient or doctor's office setting as part of a physician’s service.
Medicaid eligibility and benefit plans vary from state-to-state. Your patient needs to understand the local state’s program’s coverage policy before treatment is initiated. Usually, use of Thyrogen will need to be considered medically necessary to be covered under the Medicaid program. Depending on the state, use of Thyrogen may require prior approval request by the state Medicaid program. If this is the case, you may fill out a prior authorization form stating your patient’s medical necessity. If the state Medicaid office approves the request, your patient will be eligible to receive Thyrogen
Not sure which one to choose? Contact ThyrogenONE for assistance
The ThyrogenONE portal provides your office online access to help you and your patients :
- Submit and track benefit verifications
- Coordinate orders
- Generate automatic alerts
Dedicated ThyrogenONE Case Managers can assist you and your patients with the following.
- Benefits Verification
- Information on Ordering
- Information on specialty pharmacy fulfillment
Important Safety Information and Indications
Important Safety Information and Indications
IMPORTANT SAFETY INFORMATION
If Thyrogen is administered with radioiodine, the contraindications to radioiodine also apply to this combination regimen. Refer to the radioiodine prescribing information for a list of contraindications for radioiodine.
WARNINGS AND PRECAUTIONS
- There have been reports of death in non-thyroidectomized patients and in patients with distant metastatic thyroid cancer in which events leading to death occurred within 24 hours after administration of Thyrogen. Caution should be exercised in patients who have substantial thyroid tissue still in situ or functional thyroid cancer metastases, specifically in the elderly and those with a known history of heart disease.
- Hospitalization for administration of Thyrogen and post-administration observation in patients at risk should be considered.
- There are post marketing reports of stroke in young women with risk factors for stroke, and neurological findings suggestive of stroke (e.g., unilateral weakness) occurring within 72 hours of Thyrogen administration in patients without known central nervous system metastases. The relationship between Thyrogen administration and stroke is unknown. Patients should be well-hydrated prior to treatment with Thyrogen.
Sudden Rapid Tumor Enlargement:
- Sudden, rapid and painful enlargement of residual thyroid tissue or distant metastases can occur following treatment with Thyrogen. Pretreatment with glucocorticoids should be considered for patients in whom tumor expansion may compromise vital anatomic structures.
Risks Associated with Radioiodine Treatment:
- If Thyrogen is administered with radioiodine (RAI), the warnings and precautions for RAI apply to this combination regimen. Refer to the RAI prescribing information for a full list of the warnings and precautions for RAI.
The most common adverse reactions reported in clinical trials were nausea and headache.
USE IN SPECIFIC POPULATIONS
- If Thyrogen is administered with radioiodine, the combination regimen is contraindicated in pregnant women.
- Available data with Thyrogen use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
- The concomitant use of Thyrogen and radioiodine (RAI) is contraindicated in lactating women. If Thyrogen is administered with RAI for diagnostic use, discontinue breastfeeding after RAI administration because of the potential for serious adverse reactions from RAI in the breastfed infant.
- If Thyrogen is not administered with RAI, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Thyrogen and any potential adverse effects on the breastfed child. There are no available data on the presence of thyrotropin alfa in human milk, the effects on the breastfed infant, or the effects on milk production.
Pediatric Use: Safety and effectiveness in pediatric patients have not been established.
Geriatric Use: Results from controlled trials do not indicate a difference in the safety and efficacy of Thyrogen between adult patients less than 65 years and those over 65 years of age.
Renal Impairment: Elimination of Thyrogen is significantly slower in dialysis-dependent end stage renal disease patients, resulting in prolonged elevation of TSH levels.
INDICATIONS AND USAGE
Thyrogen® (thyrotropin alfa) is a thyroid stimulating hormone indicated for:
Adjunctive Diagnostic Tool for Well-Differentiated Thyroid Cancer: Use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer who have previously undergone thyroidectomy.
Limitations of Use:
- Thyrogen-stimulated Tg levels are generally lower than, and do not correlate with Tg levels after thyroid hormone withdrawal.
- Even when Thyrogen-Tg testing is performed in combination with radioiodine imaging, there remains a risk of missing a diagnosis of thyroid cancer or underestimating the extent of the disease.
- Anti-Tg Antibodies may confound the Tg assay and render Tg levels uninterpretable.
Adjunct for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer: Use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer.
Limitations of Use:
- The effect of Thyrogen on thyroid cancer recurrence greater than 5 years post-remnant ablation has not been evaluated.
Click here for full Prescribing Information